Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: Results from a double-blind study

Pharmacopsychiatry

Volumn 30, Issue 2, 1997, Pages 35-42

  Meyer Lindenberg, A ^a   Gruppe, H ^a   Bauer, Ulrike ^a   Lis, Stefanie ^a   Krieger, S ^a   Gallhofer, B ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OXAZEPAM;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

EID: 0030887036     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979481     Document Type: Article

References (31)

1. rd ed. rev. American Psychiatric Press, Washington, DC (1987)
2. Andreasen, N. C.: Negative symptoms in schizophrenia: Definition and reliability. Arch. Gen. Psychiat. 39 (1982) 784-788
3. Baldessarini, R., F. R. Frankenburg: Clozapine: a novel antipsychotic drug. New Engl. J. Med. 324 (1991) 746-754
4. Barnas, C., C. H. Stuppack, C. Miller, C. Haring, B. Sperner-Unterweger, W. W. Fleischhacker: Zotepin: Die Behandlung schizophrener Patienten mit vorherrschender Negativsymptomatik. Eine Doppelblindstudie vs. Haloperidol. Fortschr. Neurol. Psychiatr. 59 Suppl. 1 (1991) 36-40
5. Barnas, C., C. H. Stuppack, C. Miller, C. Haring, B. Sperner-Unterweger, W. W. Fleischhacker: Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. Int. Clin. Psychopharmacol. 7 (1992) 23-27
6. Buchanan, R. W., C. Holstein, A. Breier: The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry 36 (1994) 717-725
7. CIPS (Collegium Internationale Psychiatriae Scalarum): Internationale Skalen für Psychiatrie. Beltz Test GmbH, Weinheim (1986)
8. Colby, C. L.: The neuroanatomy and neurophysiology of attention. J Child Neurol. 6 (1991) 90-118
9. Cushman, L., B. Caplan: Multiple memory systems: evidence from stroke. Percept. Mot. Skills 64 (1987) 571-577
10. Damasio, A., S. W. Anderson: The frontal lobes. In: Heilman, K. M., E. Valenstein (eds.): Clinical Neuropsychology. Oxford University Press, New York (1993) pp. 409-460
11. Dieterle, D. M., M. Ackenheil, F. Muller-Spahn, H. P. Kapfhammer: Zotepine, a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiat. 20 (1987) 52-57
12. Dieterle, D. M., F. Muller-Spahn, M. Ackenheil: Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten. Fortschr. Neurol. Psychiatr. 59 Suppl. 1 (1991) 18-22
13. Fleischhacker, W. W., C. Barnas, C. H. Stuppack, B. Sperner-Unterweger, C. Miller, H. Hinterhuber: Zotepin vs. Haloperidol bei paranoider Schizophrenie: eine Doppelblindstudie. Fortschr. Neurol. Psychiatr. 59 Suppl. 1 (1991) 10-13
14. Gallhofer, B., U. Bauer, H. Gruppe, S. Krieger, S. Lis: First episode schizophrenia: the importance of compliance and preserving cognitive function. J. Pract. Psychiatry Behav. Health 2 (1996) 16-24
15. Goldberg, T. E., D. R. Weinberger. The effects of clozapine on neurocognition: an overview. J. Clin. Psychiatry 55 Suppl. B (1994) 88-90
16. Hagger, C., P. Buckley, J. T. Kenny, L. Friedman, D. Ubogy, H. Y. Meltzer: Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients. Biol. Psychiatry 34 (1993) 702-712
17. Kane, J. M., G. Honigfeld, J. Singer, H. Y. Meltzer and Clozaril collaborative study group: Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiat. 45 (1988) 789-796
18. Karnath, H. O., C. W. Wallesch, P. Zimmermann: Mental planning and anticipatory processes with acute and chronic frontal lobe lesions: a comparison of maze performance in routine and non-routine situations. Neuropsychologia 29 (1991) 271-290
19. Klieser, E., E. Lehmann, J. Teggeler: Doppelblindvergleich von 3 x 75 mg Zotepin und 3 x 4 mg Haloperidol bei akut schizophrenen Patienten. Fortschr. Neurol. Psychiatr. 59 Suppl. 1 (1991) 14-17
20. Lee, M. A., P. A. Thompson, H. Y. Meltzer: Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry 55 Suppl. B (1994) 82-87
21. Lingjaerde, O., U. G. Ahlfors, P. Bech et al.: The UKU side effect rating scale. Acta Psychiat. Scand. 76 Suppl. 334 (1987)
22. Meltzer, H.Y.: The mechanism of action of novel atypic antipsychotic drugs. Schizophrenia Bull. 17 (1991) 263-287
23. Milner, B.: Visually guided maze learning in man: effects of bilateral hippocampal, bilateral frontal, and unilateral cerebral lesions. Neuropsychologia 3 (1965) 317-338
24. Murphy, T. J., A. S. DeWolfe: Planning abilities in alcoholics, process and reactive schizophrenics, and normals. Int. J. Addict. 24 (1989) 435-444
25. Overall, J. E., D. R. Gorham: Brief psychiatric rating scale. Psychol. Reports 10 (1962) 799-812
26. Porteus, S. D.: Porteus maze test: fifty years' application. Pacific, Palo Alto, California (1965)
27. Riddle, M., A. H. Roberts: Psychosurgery and the porteus maze tests: review and reanalysis of data. Arch. Gen. Psychiat. 35 (1978) 493-497
28. Sachs, L: Angewandte Statistik. Springer, Berlin (1992).
29. Tremblay, M., D. Lacroix, Y. Chaput, V. Fraile, R. Lamer, J. M. Albert: Brain activation with a maze test: an EEG coherence analysis study in healthy subjects. Neuroreport. 5 (1994) 2449-2453
30. Winer, B. J.: Statistical principles in experimental design, second edition. McGraw-Hill, New York (1971)
31. Winocur, G., M. Moscovitch: Hippocampal and prefrontal cortex contribution to learning and memory: Analysis of lesion and aging effects on maze learning in rats. Behav. Neurosci. 104 (1990) 544-551